Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Peptides. 2011 Aug 16;32(9):1840–1848. doi: 10.1016/j.peptides.2011.08.010

Figure 5.

Figure 5

Peptide 8–9 demonstrates anti-tumorigenic activity in a murine Kaposi’s sarcoma model. Seven-week-old nude mice were injected in the flank with 5 × 106 KS-IMM cells. Animals received peritumoral injection (or intraperitoneal injection, data not shown) of 150 µL of 500 nM peptide 8–9 three times a week starting on day 0 (-■-). Control animals were injected with vehicle alone (-●-). a) Tumor growth was significantly reduced by peritumoral with peptide 8–9 treatment compared to vehicle alone (***p <0.001, **p <0.01, two-way ANOVA). b) Histology of treated and untreated tumors. Peritumoral (c) and intraperitoneal (d) treatments with peptide 8–9 resulted in a decrease in tumor vascularity and cellularity compared with control tumor (b) (magnification 400×).